^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA mutation

    i
    Other names: BRCA, Breast cancer, early onset
    Related biomarkers:
    Expression
    CNA
    Others
    1d
    LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. (PubMed, Genome Biol)
    Our findings unveil a novel regulatory mechanism of L1 m6A that governs the DNA damage repair response, providing a potential strategy of targeting METTL3 in combination with PARPi for cancer therapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • METTL3 (Methyltransferase Like 3)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib)
    2d
    Cervical cancer with BRCA1 gene mutations: case reports and literature review. (PubMed, Front Oncol)
    In patients with cervical cancer, BRCA testing holds important clinical value, particularly for the management of those with a significant family history of malignancy or confirmed hereditary predisposition. Appropriate genetic counseling plays an essential role in guiding preventive strategies, facilitating early diagnosis, and supporting informed decision-making regarding potential prophylactic interventions.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • BRCA mutation
    2d
    Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers. (PubMed, Oncol Rev)
    Future directions emphasize next-generation ICIs, optimized combination regimens, and AI-driven biomarker integration to achieve durable, personalized treatments. This review underscores the potential of immunotherapy to redefine TNBC management while highlighting the imperative for continued innovation to address unmet clinical needs.
    Review • Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    3d
    JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models. (PubMed, Br J Cancer)
    These results suggest the scientific rationale for further clinical development of JPI-547 for treating both PARP inhibitor-sensitive patients and those resistant to first-generation PARP inhibitors in BRCA-mutated cancers.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • nesuparib (JPI-547)
    3d
    Two decades of PARP inhibitor synthetic lethality in cancer. (PubMed, Nature)
    The significance of these discoveries spread beyond BRCA1-mutant and BRCA2-mutant cancers: the synthetic lethal concept of the BRCA-PARP inhibitor effect highlighted the myriad levels of functional redundancy that exist in tumour cells and stimulated the search for other tumour-specific synthetic lethal effects that could be exploited therapeutically. Here we distill the learnings from the past two decades in this field.
    Review • Journal • BRCA Biomarker • PARP Biomarker • BRCA Companion diagnostic • PARP Companion diagnostic
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    3d
    Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial. (PubMed, Int J Gynecol Cancer)
    These data confirm that the use of olaparib as long-term maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer is tolerable. Adverse events occurred early, were manageable, and few occurred with late onset.
    Clinical • P3 data • Journal • Adverse events • BRCA Biomarker • PARP Biomarker • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    4d
    Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial (clinicaltrials.gov)
    P2, N=30, Recruiting, Massachusetts General Hospital | Trial completion date: Mar 2027 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation
    |
    Guardant360® CDx
    |
    Talzenna (talazoparib)
    4d
    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=85, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Aug 2030 --> May 2027 | Trial primary completion date: Jan 2030 --> May 2027
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation • FOLH1 positive
    |
    Lynparza (olaparib) • FPI-2265
    6d
    RAINFOL™-07: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov)
    P3, N=688, Not yet recruiting, Genmab
    New P3 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • HRD • BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • Rina-S (rinatabart sesutecan)
    6d
    Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience. (PubMed, Cancers (Basel))
    In addition, metastatic site distribution was independently prognostic for survival outcomes and may support baseline risk stratification at the time of PARPi initiation. Further studies of predictive markers of response and resistance, as well as sequencing with platinums and combinations with other targeted agents, are needed to optimize the benefits of PARPi in this patient population.
    Clinical data • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    9d
    A potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer. (PubMed, J Ovarian Res)
    The pattern of mutation-defined POLE/MMR/TP53 group classifications varied in histological subtypes, FIGO stage and clinical outcomes in BRCA wild type EOC. BRCA wild type EOC patients with POLEmut or NSMP had favorable survival than those with MMRmut or TP53mut. The panel could be a potential marker for EOC patients.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • BRCA (Breast cancer early onset) • MSH3 (MutS Homolog 3) • PMS1 (PMS1 protein homolog 1)
    |
    TP53 mutation • BRCA wild-type • BRCA mutation
    10d
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)